Beatriz Guglieri-López1, Alejandro Pérez-Pitarch2, Dirk Jan A R Moes3, Begoña Porta-Oltra4, Mónica Climente-Martí4, Henk Jan Guchelaar3, Matilde Merino-Sanjuán5,6. 1. Pharmacy Department, Doctor Peset University Hospital of Valencia, Gaspar Aguilar Avenue, 90, 46017, Valencia, Spain. guglieri_bea@gva.es. 2. Pharmacy Department, University Clinical Hospital of Valencia, Blasco Ibañez Avenue, 17, 46010, Valencia, Spain. 3. Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands. 4. Pharmacy Department, Doctor Peset University Hospital of Valencia, Gaspar Aguilar Avenue, 90, 46017, Valencia, Spain. 5. Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Valencia, Vicent Andrés Estellés Avenue, 46100, Burjassot, Valencia, Spain. 6. Molecular Recognition and Technological Development Institute, Centro Mixto Universidad Politécnica de Valencia-Universidad de Valencia, Valencia, Spain.
Abstract
PURPOSE: Lenalidomide disease-specific toxicity profiles and potentially life-threatening adverse events support the consideration of diversity in starting doses. The aim of this study was to conduct a population pharmacokinetic analysis of lenalidomide in multiple myeloma patients to identify and evaluate non-studied covariates that could be used for dose individualization. METHODS: Blood samples were collected from 15 multiple myeloma patients. Nonlinear mixed-effects modeling was used to develop a population pharmacokinetic model and perform covariate analysis. The developed model was used to simulate dose schedules in order to explore the need of different dosing regimens in patients with different covariate values. RESULTS: The data were accurately described by a one-compartment model with first-order elimination. Absorption was best described using three transit compartments. Creatinine clearance and body surface area were identified as covariates affecting apparent clearance and apparent volume of distribution, respectively. Simulations revealed that lower starting doses than the standard 25 mg/daily could be used in patients with body surface area below 1.8 m2 and even higher doses might be necessary for patients with normal renal function and large body surface area. CONCLUSIONS: This study identified creatinine clearance and body surface area as covariates that have a clinically relevant impact on lenalidomide pharmacokinetics using population pharmacokinetics. In addition, the developed population pharmacokinetic model can be used to individualize lenalidomide dose in multiple myeloma patients, taking into account not only creatinine clearance but also body surface area.
PURPOSE:Lenalidomide disease-specific toxicity profiles and potentially life-threatening adverse events support the consideration of diversity in starting doses. The aim of this study was to conduct a population pharmacokinetic analysis of lenalidomide in multiple myelomapatients to identify and evaluate non-studied covariates that could be used for dose individualization. METHODS: Blood samples were collected from 15 multiple myelomapatients. Nonlinear mixed-effects modeling was used to develop a population pharmacokinetic model and perform covariate analysis. The developed model was used to simulate dose schedules in order to explore the need of different dosing regimens in patients with different covariate values. RESULTS: The data were accurately described by a one-compartment model with first-order elimination. Absorption was best described using three transit compartments. Creatinine clearance and body surface area were identified as covariates affecting apparent clearance and apparent volume of distribution, respectively. Simulations revealed that lower starting doses than the standard 25 mg/daily could be used in patients with body surface area below 1.8 m2 and even higher doses might be necessary for patients with normal renal function and large body surface area. CONCLUSIONS: This study identified creatinine clearance and body surface area as covariates that have a clinically relevant impact on lenalidomide pharmacokinetics using population pharmacokinetics. In addition, the developed population pharmacokinetic model can be used to individualize lenalidomide dose in multiple myelomapatients, taking into account not only creatinine clearance but also body surface area.
Entities:
Keywords:
Lenalidomide; Multiple myeloma; Personalized medicine; Population pharmacokinetics
Authors: Jim H Hughes; Mitch A Phelps; Richard N Upton; Stephanie E Reuter; Yue Gao; John C Byrd; Michael R Grever; Craig C Hofmeister; Guido Marcucci; William Blum; Kristie A Blum; David J R Foster Journal: Br J Clin Pharmacol Date: 2019-02-27 Impact factor: 4.335
Authors: Jim H Hughes; Richard N Upton; Stephanie E Reuter; Darlene M Rozewski; Mitch A Phelps; David J R Foster Journal: Cancer Chemother Pharmacol Date: 2019-09-06 Impact factor: 3.333
Authors: Xu Steven Xu; Meletios A Dimopoulos; Pieter Sonneveld; P Joy Ho; Andrew Belch; Merav Leiba; Marcelo Capra; David Gomez; Eva Medvedova; Shinsuke Iida; Chang-Ki Min; Jordan Schecter; Richard Jansson; Liping Zhang; Yu-Nien Sun; Pamela L Clemens Journal: Adv Ther Date: 2018-10-29 Impact factor: 3.845
Authors: Ted G Xiao; Jared A Weis; F Scott Gayzik; Alexandra Thomas; Akiko Chiba; Metin N Gurcan; Umit Topaloglu; Abhilash Samykutty; Lacey R McNally Journal: Photoacoustics Date: 2018-07-27